PRALUENT: payments to doctors
Payments that named PRALUENT as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $5.1M
- Providers
- 14,561
- Transactions
- 53,819
- Average per transaction
- $95
The per-transaction average — $95 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 14,561 providers the average total is $352, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sanofi-aventis U.S. LLC | $3,219,961 | 62.8% |
| Regeneron Healthcare Solutions, Inc. | $1,268,551 | 24.7% |
| Regeneron | $532,132 | 10.4% |
| Sanofi US Services Inc. | $107,149 | 2.1% |
| Sanofi | $1,000 | 0.0% |